Integrated DNA Technologies is expanding its Archer portfolio of comprehensive genomic profiling (CGP) solutions to include homologous recombination deficiency (HRD) assessment.
Available as a standalone assay, spiked-in as a supplementary module or integrated in an Archer NGS panel, the new HRD module complements existing Archer microsatellite (MSI) and tumor mutational burden (TMB) assessment capabilities to create a flexible, customizable CGP solution for labs looking to optimize sequencing resources. HRD assessment is available via the:
- VARIANTPlex HRD Module—available as a spike-into other Archer panels or ran alone.
- VARIANTPlex Complete Solid Tumor v2 panel—expands Archer’s existing Complete Solid Tumor panel, now capable of assessing HRD.
- VARIANTPlex Pan Solid Tumor v2 panel—expands Archer’s existing Pan Solid Tumor panel, now capable of assessing HRD.
Powered by Archer’s Anchored Multiplex PCR (AMP) chemistry and Archer Analysis, the new HRD module and updated Archer NGS panels enable downstream applications of precision medicine, provides a differentiated solution that can be customized to fit a lab’s solid tumor research needs, and expands Archer’s existing CGP portfolio.
